Tenvie Therapeutics Appoints Don O’Sullivan, Ph.D., MBA, as Chief Business OfficerSeasoned biotechnology executive with more than 20 years of corporate and business development experience to lead strategic collaborations and business operations
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive OfficerProven drug development leader to drive company’s pipeline of highly CNS-penetrant and precision-designed peripherally restricted small molecules toward clinical milestones
Tenvie Therapeutics Launches with $200 Million to Deliver Breakthrough Small Molecule TherapiesAdvancing a deep pipeline of therapeutics focused on treating neurological, cardiometabolic, and ophthalmic diseases
